Correlation Between UCB SA and Vertex Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both UCB SA and Vertex Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining UCB SA and Vertex Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between UCB SA ADR and Vertex Pharmaceuticals, you can compare the effects of market volatilities on UCB SA and Vertex Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in UCB SA with a short position of Vertex Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of UCB SA and Vertex Pharmaceuticals.

Diversification Opportunities for UCB SA and Vertex Pharmaceuticals

-0.81

Correlation Coefficient

UCB SA  Vertex Pharmaceuticals

Pay attention - limited upside

The 3 months correlation between UCB and Vertex is -0.81. Overlapping area represents the amount of risk that can be diversified away by holding UCB SA ADR and Vertex Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Vertex Pharmaceuticals and UCB SA is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on UCB SA ADR are associated (or correlated) with Vertex Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Vertex Pharmaceuticals has no effect on the direction of UCB SA i.e., UCB SA and Vertex Pharmaceuticals go up and down completely randomly.

Pair Corralation between UCB SA and Vertex Pharmaceuticals

Assuming the 90 days horizon UCB SA ADR is expected to generate 1.1 times more return on investment than Vertex Pharmaceuticals. However, UCB SA is 1.1 times more volatile than Vertex Pharmaceuticals. It trades about 0.19 of its potential returns per unit of risk. Vertex Pharmaceuticals is currently generating about -0.17 per unit of risk. If you would invest  6,253  in UCB SA ADR on January 25, 2024 and sell it today you would earn a total of  273.00  from holding UCB SA ADR or generate 4.37% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

UCB SA ADR  vs.  Vertex Pharmaceuticals

UCB SA ADR

Risk-Adjusted Performance

25 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in UCB SA ADR are ranked lower than 25 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak forward-looking indicators, UCB SA showed solid returns over the last few months and may actually be approaching a breakup point.

Vertex Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Vertex Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unfluctuating performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

Pair Trading with UCB SA and Vertex Pharmaceuticals

The main advantage of trading using opposite UCB SA and Vertex Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if UCB SA position performs unexpectedly, Vertex Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vertex Pharmaceuticals will offset losses from the drop in Vertex Pharmaceuticals' long position.

The idea behind UCB SA ADR and Vertex Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.